IFNAR1 Monoclonal Antibody (MAR1-5A3), Functional Grade, eBioscience™, Invitrogen™

Description

• Description: The MAR1-5A3 monoclonal antibody reacts with mouse IFN alpha/beta receptor subunit 1 (IFNAR-1)
• The type I IFN receptor subunit 1 is co-expressed with IFNAR-2 on nearly all cells and make up the heterodimeric receptor complex that binds to all type I IFNs, IFN alpha and IFN beta
• Type I IFNs are a group of structurally and functionally related proteins that demonstrate antiviral, antiparasitic, and antiproliferative activities
• Applications Reported: The MAR1-5A3 antibody has been reported for use in neutralization of IFNAR1 bioactivity
• Applications Tested: The Functional Grade Purified MAR1-5A3 antibody has been tested by LAL assay to verify low endotoxin levels, by bioassay for neutralization of mouse IFNAR-1bioactivity
• The MAR1-5A3 antibody at 0.04 μg/mL has been found to inhibit by 50% the biological effects of 0.5 ng/mL mouse IFN-a2 (ND50), in an EMCV assay of L929 cell protection
• Detailed information and protocols about cytokine bioassays and in vitro cytokine neutralization using antibodies can be found in Best Protocols® section
• Storage and handling: Use in a sterile environment
• Filtration: 0.2 μm post-manufacturing filtered
• Purity: Greater than 90%, as determined by SDS-PAGE
• Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay
• Aggregation: Less than 10%, as determined by HPLC
• Interferons are widely used therapeutic agents because of their anti tumor and antiviral effects and because of their modulatory effects on the immune system (Biron,2001, Kirkwood, 2002)
• These cytokines produce their effects by binding to the Type 1 Interferon-& Receptor (IFNAR1)
• Down regulation of this receptor plays a key role in determining the magnitude and duration of cytokine signaling
• This down regulation is thought to be influenced by phosphorylation of Serine 535 and 539 in the IFNAR1 (Kumar et al., 2003).